Skip to main content

Table 1 Baseline characteristics of all participants

From: Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial

 

7-day STT

10-day BQT

P value

(n = 177)

(n = 175)

Age (year), Mean ± SD

55.6 ± 11.3

53.9 ± 10.7

0.147

Sex, no. (%)

  

0.920

 Male

83 (46.9)

83 (47.4)

 

 Female

94 (53.1)

92 (52.6)

 

Smoking, no. (%)

  

0.196

 Never

116 (65.5)

103 (58.9)

 

 Current or former smoker

61 (34.5)

72 (41.1)

 

Alcohol, no. (%)

  

0.028

 Never

82 (46.3)

61 (34.9)

 

 Current or former alcohol drinker

95 (53.7)

114 (65.1)

 

Family history of gastric cancer, no. (%)

65 (36.7)

61 (34.9)

0.715

Coexisting illness, no. (%)

   

 Hypertension

37 (20.9)

43 (24.6)

0.412

 Diabetes mellitus

11 (6.2)

13 (7.4)

0.651

Indications for H. pylori treatment, no. (%)

   

 Post-ESD for adenoma or gastric cancer

55 (31.1)

51 (29.1)

0.693

 Peptic ulcer disease

22 (12.4)

27 (15.4)

0.416

 Chronic gastritis with non-ulcer dyspepsia

100 (56.5)

97 (55.4)

0.840

  1. STT, proton-pump inhibitor-clarithromycin containing standard triple therapy; BQT, bismuth-containing quadruple therapy; SD, standard deviation; ESD, endoscopic submucosal dissection